Related Experiment Videos
Serum osteocalcin (BGP) in tumor-associated hypercalcemia
1Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgique.
Summary
Serum osteocalcin (BGP) is a marker of bone formation. In hypercalcemic cancer patients, BGP levels were slightly elevated and normalized after treatment, indicating its potential role in monitoring bone turnover.
Area of Science:
- Endocrinology
- Oncology
- Biochemistry
Background:
- Serum osteocalcin (BGP) is recognized as a marker for bone formation.
- Tumor-associated hypercalcemia is a complication of various cancers.
- Assessing bone turnover is crucial in managing hypercalcemia.
Purpose of the Study:
- To evaluate serum osteocalcin (BGP) as a marker of bone formation in tumor-associated hypercalcemia.
- To compare BGP levels in hypercalcemic cancer patients with healthy subjects.
- To assess the changes in BGP levels after successful treatment of hypercalcemia.
Main Methods:
- Measured serum BGP concentrations in 54 untreated hypercalcemic cancer patients and 109 healthy controls.
- Re-evaluated BGP levels in 22 patients after treatment with aminohydroxypropylidene diphosphonate (APD).
- Analyzed correlations between BGP levels and clinical parameters (age, sex, renal function, tumor site, histology, bone metastases, calcium, alkaline phosphatase, parathyroid function).
Main Results:
- Mean BGP levels were significantly higher in hypercalcemic patients (4.6 ng/ml) than in healthy subjects (3.6 ng/ml).
- BGP levels normalized in patients after successful hypercalcemia treatment.
- No significant correlation was found between BGP levels and tumor site, histology, bone metastasis, or other bone metabolism parameters.
Conclusions:
- Serum osteocalcin (BGP) is slightly elevated in tumor-associated hypercalcemia.
- BGP levels normalize after successful treatment of hypercalcemia.
- BGP exhibits wide variations in hypercalcemic patients, irrespective of metastatic involvement, suggesting complex regulation.